Testing effectiveness (Phase 2)Looking for participantsNCT06003621What this trial is testingTiragolumab and Atezolizumab in Advanced Pan-cancer PatientsWho this might be right forSolid Tumor, Adult Omico 96
Testing effectiveness (Phase 2)WithdrawnNCT05041972What this trial is testingARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)Who this might be right forHER2 Mutation-Related TumorsHER2 Amplified Solid Tumors Ambrx, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT06279130What this trial is testingPan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsWho this might be right forResectable MMR-deficient Solid TumorsResectable MMR-proficient Solid Tumors The Netherlands Cancer Institute 133
Early research (Phase 1)Study completedNCT01703481What this trial is testingEvaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaWho this might be right forTumor or Lymphoma Janssen Research & Development, LLC 188
Not applicableLooking for participantsNCT07504367What this trial is testingLarge Language Models Assist in Tumor MDTWho this might be right forLung CancerBreast CancerColorectal Cancer+2 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 60
Early research (Phase 1)Active Not RecruitingNCT06607185What this trial is testingThe Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsWho this might be right forPancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer+2 more Eli Lilly and Company 750
Not applicableStudy completedNCT00299195What this trial is testingStudy of Sulindac in Oral Premalignant LesionsWho this might be right forLeukoplakia, OralBenign Neoplasms Memorial Sloan Kettering Cancer Center 63
Early research (Phase 1)Looking for participantsNCT06096974What this trial is testingPan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRASWho this might be right forAdvanced Solid Tumors Shanghai YingLi Pharmaceutical Co. Ltd. 60
Early research (Phase 1)Study completedNCT01962532What this trial is testingEvaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or LymphomaWho this might be right forNeoplasmsLymphomaAdenocarcinoma+1 more Janssen Research & Development, LLC 19
Large-scale testing (Phase 3)UnknownNCT05698082What this trial is testingFOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent TissuesWho this might be right forColorectal CancerMonkey Pox xiaoliang Huang 120
Not applicableNot Yet RecruitingNCT07422103What this trial is testingPAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)Who this might be right forPancreatic CancerPancreatic DiseasesGastrointestinal Symptoms+3 more Casa di Cura Dott. Pederzoli 158
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06055166What this trial is testingA Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid TumorsWho this might be right forPARP Inhibitor for Esophageal Squamous Cell Carcinoma Chongqing University Cancer Hospital 120
Not applicableActive Not RecruitingNCT04405557What this trial is testingThe PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant TumorWho this might be right forEarly Detection of Cancer Geneplus-Beijing Co. Ltd. 757
Large-scale testing (Phase 3)Not Yet RecruitingNCT07336953What this trial is testingA Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)Who this might be right forPDAC - Pancreatic Ductal Adenocarcinoma West China Hospital 198
Not applicableLooking for participantsNCT06822413What this trial is testingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisWho this might be right forCancer DiagnosisLiver Cancer, AdultCancer Screening+14 more Second Affiliated Hospital, School of Medicine, Zhejiang University 600
Testing effectiveness (Phase 2)Active Not RecruitingNCT02365597What this trial is testingAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerWho this might be right forUrothelial Cancer Janssen Research & Development, LLC 239
Not applicableWithdrawnNCT01888562What this trial is testingPonatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial CarcinomaWho this might be right forEndometrial Neoplasms Washington University School of Medicine
Not applicableLooking for participantsNCT05663515What this trial is testingA Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsWho this might be right forPancreatic Cancer AstraZeneca 24,000
Not applicableLooking for participantsNCT07404202What this trial is testingA Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor PatientsWho this might be right forPan-tumor(NSCLC, GYN Cancers, BTC and UC) AstraZeneca 2,100
Early research (Phase 1)Study completedNCT01976741What this trial is testingDose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)Who this might be right forNeoplasms Bayer 168